RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study

Mayur S. Ramesh, MD, Henry Ford Hospital System, Detroit, MI; Bharat Misra, MD, Borland-Groover Clinic, Jacksonville, FL; Arnab Ray, MD, Robert Smith, MD, Ochsner Clinic, New Orleans, LA; Mary Kay Sobcinski, RN, MHA, Rebiotix Inc, Roseville, MN

RBX2660 (microbiota suspension) for Recurrent C. difficile Infection

Download this poster (697 KB)
Download the abstract (342 KB)

American College of Gastroenterology
October 17-20, 2014, Philadelphia, PA

The risk of recurrence increases significantly with each subsequent recurrence of Clostridium difficile infection.


The purpose of the PUNCH CD study was to assess the safety of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection. RBX2660 is a biologic drug consisting of a suspension of live human-derived intestinal microbes. A secondary objective of the study was Clostridium difficile infection resolution at 8 weeks.